ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eckert & ziegler radiopharma gmbh - 68 ge - 68 ga - radionuclide generator - 0,74-1,85 gbq - germanium (ge-68) chloride; gallium (ga-68) chloride - various diagnostic radiopharmaceuticals

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

21st century homeopathics, inc - active ingredients: allium sativum 4x-30c, aurum metallicom 12-30x, belladonna 30c, berberis vulgaris 30c, causticum 30c, cornium maculatum 30 c, hepar sulphuris calcareum 30c, hypericum perforatum 30c, ipecacuanha 30c, metal isode 12-30x (aluminum, argentum metallicum, arsenicum metallicum, baryta carbonica, beryllium metallicum, boron, bromium, cadmium metallicum, carboneum, cerium, cesium, chromium, cobalt, cuprum metallicum, dysprosium, erbium, europium, ferrum metallicum, fluorine, gadolinium, gallium, - indications: temporary relief of neurological disorders, vomiting, prostration and metallic aftertaste. remedy #7 supports detoxification of environmental pollutants. heavy metal detox

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ohm pharma inc. - activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), ceanothus americanus leaf (unii: 25b1y14t8n) (ceanothus americanus leaf - unii:25b1y14t8n), galium aparine (unii: z4b6561488) (galium aparine - unii:z4b6561488), veronicastrum virginicum root (unii: m2o62ytn42) (culver's root - unii:m2o62ytn42), mandragora officinarum root (unii: i2xcb174vb) (mandragora officinarum root - unii:i2xcb174vb), momordica balsamina immature fruit (unii: wuw1665v10) (momordica balsamina immature fr - uses: temporarily relieves functional ailments of the endocrine/exocrine pancreas.** **this statement has not been evaluated by the fda. it is based on documented homeopathic materia medica. functional ailments of the endrocrine/exocrine pancreas relief

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ohm pharma inc. - activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), ceanothus americanus leaf (unii: 25b1y14t8n) (ceanothus americanus leaf - unii:25b1y14t8n), galium aparine (unii: z4b6561488) (galium aparine - unii:z4b6561488), veronicastrum virginicum root (unii: m2o62ytn42) (culver's root - unii:m2o62ytn42), mandragora officinarum root (unii: i2xcb174vb) (mandragora officinarum root - unii:i2xcb174vb), momordica balsamina immature fruit (unii: wuw1665v10) (momordica balsamina immature fr - uses: temporarily relieves functional ailments of the endocrine/exocrine pancreas.**

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - saflufenacil; trifludimoxazin - suspension concentrate - saflufenacil amine-uracil active 250.0 g/l; trifludimoxazin active 125.0 g/l - herbicide

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

problen - turnera diffusa leafy twig (unii: rq2cfa7wwj) (turnera diffusa leafy twig - unii:rq2cfa7wwj), gallium (unii: ch46oc8yv4) (gallium - unii:ch46oc8yv4), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), sus scrofa pituitary gland (unii: l0pfemq1dt) (sus scrofa pituitary gland - unii:l0pfemq1dt), asian ginseng (unii: cuq3a77yxi) (asian ginseng - unii:cuq3a77yxi), nuphar lutea leaf (unii: dg9a33o77k) (nup - uses: temporarily supports the body to rebalance libido function and support sexual desire. symptoms may include: decreased sex drive and vitality, lack of ambition or vigor.*

シンガポール - 英語 - HSA (Health Sciences Authority)

labgistics asia pte ltd - germanium (68ge) chloride; gallium (68ga) chloride - injection, solution (radiopharmaceutical) - germanium (68ge) chloride 0.74 – 1.85 gbq; gallium (68ga) chloride > 60 % of the loaded activity

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate 500 mg - desferal is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. desferal is indicated for the treatment of transfusional iron overload in patients with chronic anemia. desferal is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). desferal is contraindicated in patients with: - a history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see description (11)] . reactions have included anaphylaxis [see warnings and precautions (5.1)] . - severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see warnings and precautions (5.3)] . risk summary there are no available data on desferal use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. in animal reproduction studies subcutaneous administration of deferoxamine to pregnan

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

gland pharma limited - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. deferoxamine mesylate for injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia. deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). deferoxamine mesylate for injection is contraindicated in patients with:  • a history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see description (11)] . reactions have included anaphylaxis [see warnings and precautions (5.1)] .  • severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see warnings and precautions (5.3)] . risk summary there are no available data on deferoxamine mesylate use in pregnant women to evaluate for a drug-associated risk of major birth defects,

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. deferoxamine mesylate is indicated for the treatment of transfusional iron overload in patients with chronic anemia. deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). deferoxamine mesylate for injection is contraindicated in patients with: risk summary there are no available data on deferoxamine mesylate use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. in animal reproduction studies subcutaneous administration of deferoxamine to pregnant animals (mice or rabbits) during organogenesis at doses approximately ≥0.2- (mice) and ≥0.7 (rabbits) times the maximum recommended human dose resulted in maternal toxicity and adverse developmental outcomes (see data). advise pregnant women of the potential risk to a fetus. consider the benefits and risks of deferoxamine mesylate for the mother and possible risks to the fetus when prescribing deferoxamine mesylate to a pregnant woman. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in an embryo-fetal developmental study in mice, pregnant animals administered subcutaneous doses of deferoxamine at 180, and 540 mg/kg/day from gestation day 7 to gestation day 12 resulted in a dose dependent delay and irregularities of fetal skeletal maturation at doses ≥0.2 times the mrhd. at the highest dose of 540 mg/kg, in 1/23 fetuses had a unilateral lesion to the eye lens (approximately 0.5 times the mrhd). in the embryo-fetal developmental studies in rabbits, pregnant animals administered subcutaneous doses of deferoxamine either 200 mg/kg or 200, 300, and 540 mg/kg from gestation day 6 to gestation day 14 resulted in maternal toxicity and embryo-fetal developmental effects at 0.7 times the mrhd. maternal toxicity included reduced fetal body weights and embryo-fetal effects included malformations of spina bifida, and increased incidence of abnormally ossified ribs and vertebrae. no maternal toxicity or embryo-fetal effects were observed in rats at deferoxamine doses tested (up to 0.9 times the mrhd). there are no data on the presence of deferoxamine or its metabolite in either human or animal milk, the effects on the breastfed child, or the effects on milk production. it is not known whether deferoxamine is excreted in human milk. because of the potential for serious adverse reactions in the breastfed child, advise patients not to breastfeed during treatment with deferoxamine mesylate, and for one week after the last dose. based on animal data, deferoxamine mesylate can cause malformations at doses less than the human dose [see use in specific populations (8.1)] . contraception females deferoxamine mesylate can cause embryo-fetal harm when administered to pregnant women [see use in specific populations (8.1)] . advise female patients of reproductive potential to use effective contraception during treatment with deferoxamine mesylate and for one month after the last dose. safety and effectiveness in pediatric patients 3 years of age and older have been established for the treatment of acute iron intoxication and for the treatment of transfusional iron overload in patients with chronic anemia. safety and effectiveness in pediatric patients under the age of 3 years have not been established. iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. deferoxamine mesylate is not recommended for use. the drug should ordinarily not be given to these patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. high doses of deferoxamine mesylate and concomitant low ferritin levels have been associated with growth suppression in pediatric patients. monitor weight and height in pediatric patients receiving deferoxamine mesylate every 3 months [see warnings and precautions (5.5), adverse reactions (6.1)] . clinical studies of deferoxamine mesylate did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from the younger subjects. postmarketing reports suggest a possible trend for an increased risk of eye disorders in the geriatric population, specifically the occurrence of color blindness, maculopathy, and scotoma. however, it is unclear if these eye disorders were dose related. although the number of reports was very small, certain elderly patients may be predisposed to eye disorders when taking deferoxamine mesylate. postmarketing reports also suggest that there may be an increased risk of deafness and hearing loss in the geriatric population [see adverse reactions (6)] . in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. deferoxamine mesylate is contraindicated in patients with severe renal disease [see contraindications (4)] . for patients with renal impairment, dose selection should usually start at the low end of the dosing range. deferoxamine can cause increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular disorders [see warnings and precautions (5.3)] . monitor patients for changes in renal function. for patients with hepatic impairment, dose selection should usually start at the low end of the dosing range.